SENJU PHARMACEUTICAL CO., LTD.

Kiora Pharmaceuticals Advances Two Phase 2 Retinal Disease Trials, Secures $110M Asian Partnership

- Kiora Pharmaceuticals initiated two Phase 2 clinical trials for retinal diseases, including KLARITY for KIO-104 treating retinal inflammation and ABACUS-2 for KIO-301 targeting vision restoration in retinitis pigmentosa patients. - The company secured a strategic partnership with Senju Pharmaceutical for KIO-301 development in Asia, potentially worth up to $110 million plus royalties, while extending KIO-104 market exclusivity to 2043. - With $20.7 million in cash and projected runway into late 2027, Kiora maintains funding beyond anticipated data readouts for both trials while actively recruiting patients across multiple sites.